GRITSTONE BIO INC. - COMMON STOCK

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

15 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Gritstone bio to Participate in Upcoming Investor and Scientific Conferences

08 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

08 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering

01 Apr 2024 23:00:00 By Nasdaq GlobeNewswire

Gritstone bio Announces Proposed Public Offering

01 Apr 2024 16:10:00 By Nasdaq GlobeNewswire

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

01 Apr 2024 16:01:56 By Nasdaq GlobeNewswire

Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

05 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Gritstone bio Announces Workforce Reduction 

29 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Gritstone bio to Participate in Upcoming Investor and Scientific Conferences

21 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial

12 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Feb 2024 16:30:00 By Nasdaq GlobeNewswire

Gritstone bio to Participate in Upcoming Investor Conference

17 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jan 2024 16:30:00 By Nasdaq GlobeNewswire

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Dec 2023 16:30:00 By Nasdaq GlobeNewswire

Gritstone bio to Participate in Upcoming Investor Conferences

20 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

08 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine

11 Oct 2023 07:10:00 By Nasdaq GlobeNewswire

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023

04 Oct 2023 16:05:21 By Nasdaq GlobeNewswire